Amazon Falls Over 10% After Earnings Report
Tech selloff that has weighed on market sentiment this week has become more widespread and indiscriminate on Thursday. Whereas Energy and Basic Materials - sectors that cannot be replaced by agentic AI - had offered investors some refuge thus far, today's selloff is rapidly morphing into a wider panic. Materials was the worst performing sector on Wednesday as traders resumed selling precious metals while also reacting to the busted Rio Tinto - Glencore deal, crypto continued to plummet, and the fever in the software space showed no signs of breaking. Moreover, the Vix fear index closed above 21 handle for the first time this year as funds rapidly rotated into Utilities and Treasuries.The opening hours of the evening session are seeing little relief following another high-profile MAG-7 name reporting disappointing results, with Amazon.comfalling over 10% afterhours. S&P e-minis are down 0.7%, Nasdaq 100 contract is off by 1.2%, and Dow Industrials is slipping by 0.4%. In commodities, WTI crude is down another 1% below $63 while gold and silver are below $4,780 and $70 per ounce respectively - the latter now down a whopping 40% from all-time highs seen just last week.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Encompass Health Corporationup 13.5%BILL Holdings, Inc.up 11.5%Dave Inc.up 8.4%Robloxup 8.0%Redditup 4.0%Fortinetup 2.9%Monolithic Powerup 2.1%DOWN AFTER EARNINGS -Doximitydown 37.2%Molinadown 33.6%Amazondown 10.7%Illuminadown 8.6%Microchipdown 7.7%Affirmdown 6.1%Atlassiandown 4.3%Paylocitydown 4.0%
Trade with 70% Backtested Accuracy
Analyst Views on EHC
About EHC
About the author

- Significant Earnings Growth: Encompass Health reported a net income of $146.30 million for Q4, translating to $1.42 per share, which marks a substantial increase from last year's $120.50 million and $1.18 per share, indicating improved profitability.
- Exceeding Market Expectations: The adjusted net income reached $148.80 million, or $1.46 per share, surpassing analysts' expectations of $1.30 per share, demonstrating the company's success in cost control and operational efficiency.
- Steady Revenue Increase: The company's Q4 revenue rose by 10% to $1.545 billion, up from $1.405 billion last year, reflecting strong market demand and business expansion.
- Optimistic Future Outlook: Encompass Health provided FY26 revenue guidance of $6.365 billion to $6.465 billion and EPS guidance of $5.81 to $6.10, showcasing the company's confidence in future growth and clear strategic planning.
- Strong Performance: Encompass Health reported Q4 2025 revenue of $1.5 billion, a 9.9% increase, while adjusted EBITDA rose 15.9% to $335.6 million, demonstrating robust market performance and enhanced profitability.
- Cost Control Success: Despite adding 517 beds, the company reduced premium labor spend by over $21 million from 2024, showcasing effective cost management alongside expansion, which strengthens financial flexibility.
- Optimistic Outlook: Management projects 2026 net operating revenue between $6.365 billion and $6.465 billion, with adjusted EBITDA of $1.34 billion to $1.38 billion, reflecting confidence in future growth and commitment to ongoing investments.
- Strategic Realignment: The company plans to introduce small-format hospitals in 2027, implementing a hub-and-spoke strategy to adapt to market demand changes, further expanding market share and enhancing service capabilities.
Market Opening: U.S. stock markets are set to open in two hours.
Encompass Health Corp. Performance: Encompass Health Corp. (EHC) saw a 16.6% increase in pre-market trading.
Bloom Energy Corp. Performance: Bloom Energy Corp. (BE) experienced a 12.4% rise in pre-market trading.
Overall Market Sentiment: The significant gains in these companies indicate positive market sentiment ahead of the market opening.
- Earnings Beat: Encompass Health reported a Q4 non-GAAP EPS of $1.46, exceeding expectations by $0.16, which reflects strong profitability and boosts investor confidence in the company's financial health.
- Significant Revenue Growth: The company achieved revenues of $1.55 billion in Q4, marking a 6.9% year-over-year increase and surpassing estimates by $10 million, indicating robust demand and competitive positioning in the market.
- Positive Market Reaction: The strong earnings report is likely to drive Encompass Health's stock price upward, attracting more investor interest and potentially enhancing the company's market valuation.
- Optimistic Future Outlook: With ongoing operational optimizations and service expansions, the company is expected to maintain its growth momentum in the coming quarters, strengthening its market position in the healthcare sector.
- Significant Revenue Growth: In Q4 2025, Encompass Health reported net operating revenue of $1.5446 billion, a 9.9% increase from Q4 2024, indicating strong performance and sustained demand in the rehabilitation hospital market.
- Earnings Per Share Improvement: Adjusted earnings per share rose from $1.17 in 2024 to $1.46, a 24.8% increase, demonstrating a significant enhancement in profitability that boosts investor confidence.
- Increased Operating Cash Flow: The company generated $346 million in cash flows from operating activities in Q4, a 24.1% increase year-over-year, providing ample funding for future expansion and investments.
- Optimistic 2026 Outlook: Encompass Health projects net operating revenue for 2026 to be between $6.365 billion and $6.465 billion, with adjusted EBITDA expected to range from $1.34 billion to $1.38 billion, reflecting confidence in future growth and rising market demand.
- Earnings Announcement Date: Encompass Health is set to release its Q4 earnings on February 5, with a consensus EPS estimate of $1.30, reflecting an 11.1% year-over-year increase, indicating ongoing improvement in profitability.
- Revenue Expectations: The anticipated revenue for Q4 is $1.54 billion, representing a 6.2% year-over-year growth, which underscores the company's robust performance in the healthcare sector and rising market demand.
- Historical Performance Review: Over the past two years, Encompass Health has consistently beaten EPS estimates 100% of the time and has surpassed revenue estimates 75% of the time, demonstrating the company's reliability and consistency in financial performance.
- Estimate Revision Dynamics: Despite having no upward revisions in EPS estimates over the last three months, with four downward revisions, and three downward revisions in revenue estimates, this may reflect a cautious market sentiment regarding the company's future performance.











